DTC
MNPR icon

Deep Track Capital’s Monopar Therapeutics MNPR Stock Holding History

Deep Track Capital’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-95,408
Closed -$6.23M – 67
2025
Q4 		$6.23M Buy
+95,408
New +$7.8M 0.11% 47

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deep Track Capital's MNPR Position: Q1 2026 in Review

Deep Track Capital sold out of Monopar Therapeutics (MNPR) in Q1 2026, closing a stake of 95,408 shares — an estimated $6.23M sold.

Deep Track Capital first reported a position in MNPR in Q4 2025 and held it in 1 quarter. The position peaked at $6.23M in Q4 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Deep Track Capital reported no remaining Monopar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Deep Track Capital sold 95,408 Monopar Therapeutics shares in Q1 2026, an estimated $6.23M.
  • Deep Track Capital first reported a position in Monopar Therapeutics in Q4 2025 and held it in 1 quarter.
  • Deep Track Capital's Monopar Therapeutics position peaked at $6.23M in Q4 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Deep Track Capital's 13F filing for Q1 2026, filed 15 May 2026.